Terminated PHASE1 INTERVENTIONAL 1-arm NCT00278564

Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases

High Dose Cyclophosphamide & ATG With Hematopoietic Stem Cell Transplantation in Patients With Refractory Idiopathic Inflammatory Myopathy Diseases: A Phase I Trial

Sponsor: Northwestern University

Conditions MYOPATHY

Interventions ATG(rabbit) Cyclophosphamide G-CSF Hematopoietic stem cell transplantation Mesna Methylprednisolone Rituxan

Updated 8 times since 2017 Last updated: Nov 3, 2017 Started: Sep 30, 2005 Primary completion: Jul 31, 2016 Completion: Jul 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

high relapse rate

Other terminated trials from Northwestern University

See all terminations from Northwestern University

Listed as NCT00278564, this PHASE1 trial focuses on MYOPATHY and remains terminated or withdrawn. Sponsored by Northwestern University, it has been updated 8 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE1
Sep 2018 — Jan 2021 [monthly]

Terminated PHASE1

▶ Show 3 earlier versions

Jun 2018 — Sep 2018 [monthly]

Terminated PHASE1
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE1
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1

First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Northwestern University

Data source: Northwestern University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States